Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. Wilhelm SM, et al. Among authors: bollag g. Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443. Cancer Res. 2004. PMID: 15466206
Discovery of a novel Raf kinase inhibitor.
Lyons JF, Wilhelm S, Hibner B, Bollag G. Lyons JF, et al. Among authors: bollag g. Endocr Relat Cancer. 2001 Sep;8(3):219-25. doi: 10.1677/erc.0.0080219. Endocr Relat Cancer. 2001. PMID: 11566613 Review.
Raf pathway inhibitors in oncology.
Bollag G, Freeman S, Lyons JF, Post LE. Bollag G, et al. Curr Opin Investig Drugs. 2003 Dec;4(12):1436-41. Curr Opin Investig Drugs. 2003. PMID: 14763129 Review.
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G. Su F, et al. Among authors: bollag g. Cancer Res. 2012 Feb 15;72(4):969-78. doi: 10.1158/0008-5472.CAN-11-1875. Epub 2011 Dec 28. Cancer Res. 2012. PMID: 22205714
Assays of human postprenylation processing enzymes.
Choi YJ, Niedbala M, Lynch M, Symons M, Bollag G, North AK. Choi YJ, et al. Among authors: bollag g. Methods Enzymol. 2001;332:103-14. doi: 10.1016/s0076-6879(01)32195-x. Methods Enzymol. 2001. PMID: 11305089 No abstract available.
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Mao M, et al. Among authors: bollag g. Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18. Clin Cancer Res. 2013. PMID: 23251002 Free PMC article.
119 results